294 related articles for article (PubMed ID: 27183546)
41. Reduction in Retinal Thickness Fluctuations After Treatment With Fluocinolone Acetonide Implant for DME: A Post-Hoc Analysis of the USER Study.
Riemann CD; Eaton AM; Cutino A
Ophthalmic Surg Lasers Imaging Retina; 2020 May; 51(5):298-306. PubMed ID: 32511735
[TBL] [Abstract][Full Text] [Related]
42. Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert.
Campochiaro PA; Hafiz G; Shah SM; Bloom S; Brown DM; Busquets M; Ciulla T; Feiner L; Sabates N; Billman K; Kapik B; Green K; Kane F;
Ophthalmology; 2010 Jul; 117(7):1393-9.e3. PubMed ID: 20202684
[TBL] [Abstract][Full Text] [Related]
43. Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis.
Jaffe GJ; McCallum RM; Branchaud B; Skalak C; Butuner Z; Ashton P
Ophthalmology; 2005 Jul; 112(7):1192-8. PubMed ID: 15921758
[TBL] [Abstract][Full Text] [Related]
44. Intraocular pressure change after injection of intravitreal dexamethasone (Ozurdex) implant in Korean patients.
Choi W; Park SE; Kang HG; Byeon SH; Kim SS; Koh HJ; Lee S; Seong GJ; Kim CY; Kim M
Br J Ophthalmol; 2019 Oct; 103(10):1380-1387. PubMed ID: 30523044
[TBL] [Abstract][Full Text] [Related]
45. The relationship between plasma MMP-9 and TIMP-2 levels and intraocular pressure elevation in diabetic patients after intravitreal triamcinolone injection.
Yildirim N; Sahin A; Erol N; Kara S; Uslu S; Topbas S
J Glaucoma; 2008; 17(4):253-6. PubMed ID: 18552607
[TBL] [Abstract][Full Text] [Related]
46. Fluocinolone acetonide for the treatment of diabetic macular edema.
Haritoglou C; Mayer W; Wolf A
Expert Rev Clin Pharmacol; 2016; 9(3):367-74. PubMed ID: 26681198
[TBL] [Abstract][Full Text] [Related]
47. OBSERVED COMPLICATIONS FROM DEXAMETHASONE INTRAVITREAL IMPLANT FOR THE TREATMENT OF MACULAR EDEMA IN RETINAL VEIN OCCLUSION OVER 3 TREATMENT ROUNDS.
Reid GA; Sahota DS; Sarhan M
Retina; 2015 Aug; 35(8):1647-55. PubMed ID: 25932545
[TBL] [Abstract][Full Text] [Related]
48. Uveitis treated with fluocinolone acetonide implants.
Viola F; Staurenghi G; Ratiglia R
Arch Ophthalmol; 2009 Jan; 127(1):115-6; author reply 116. PubMed ID: 19139357
[No Abstract] [Full Text] [Related]
49. Surgical intervention of steroid-induced ocular hypertension from Ozurdex.
Sejpal P; Scott-Weideman J
Optom Vis Sci; 2013 Jan; 90(1):e24-30. PubMed ID: 23241827
[TBL] [Abstract][Full Text] [Related]
50. Short-term safety of dexamethasone implant for treatment of macular edema due to retinal vein occlusion, in eyes with glaucoma or treated ocular hypertension.
Theodoropoulou S; Ellabban AA; Johnston RL; Cilliers H; Mohamed Q; Sallam AB
Graefes Arch Clin Exp Ophthalmol; 2017 Apr; 255(4):725-732. PubMed ID: 27878430
[TBL] [Abstract][Full Text] [Related]
51. CLINICAL EVIDENCE OF THE MULTIFACTORIAL NATURE OF DIABETIC MACULAR EDEMA.
Chakravarthy U; Yang Y; Lotery A; Ghanchi F; Bailey C; Holz FG; Downey L; Weber M; Eter N; Dugel PU
Retina; 2018 Feb; 38(2):343-351. PubMed ID: 28257378
[TBL] [Abstract][Full Text] [Related]
52. Effectiveness and tolerability of the fluocinolone acetonide implant in patients with diabetic macular edema in UAE: 12-Month results.
Elbarky AM
Eur J Ophthalmol; 2021 Nov; 31(6):3196-3202. PubMed ID: 33426902
[TBL] [Abstract][Full Text] [Related]
53. Economic evaluation of a fluocinolone acetonide intravitreal implant for patients with DME based on the FAME study.
Cutino A; Green K; Kendall R; Moore PT; Zachary C
Am J Manag Care; 2015 Jan; 21(4 Suppl):S63-72. PubMed ID: 25734663
[TBL] [Abstract][Full Text] [Related]
54. Use of flucinolone acetonide for patients with diabetic macular oedema: patient selection criteria and early outcomes in real world setting.
Elaraoud I; Andreatta W; Kidess A; Bhatnagar A; Tsaloumas M; Quhill F; Yang Y
BMC Ophthalmol; 2016 Jan; 16():3. PubMed ID: 26728265
[TBL] [Abstract][Full Text] [Related]
55. Cost-effectiveness of fluocinolone acetonide implant (ILUVIEN®) in UK patients with chronic diabetic macular oedema considered insufficiently responsive to available therapies.
Pochopien M; Beiderbeck A; McEwan P; Zur R; Toumi M; Aballéa S
BMC Health Serv Res; 2019 Jan; 19(1):22. PubMed ID: 30626376
[TBL] [Abstract][Full Text] [Related]
56. The 0.19-mg Fluocinolone Acetonide Intravitreal Implant Reduces Treatment Burden in Diabetic Macular Edema.
Merrill PT; Holekamp N; Roth D; Kasper J; Grigorian R;
Am J Ophthalmol; 2023 Apr; 248():16-23. PubMed ID: 36223849
[TBL] [Abstract][Full Text] [Related]
57. BETTER BASELINE VISION LEADS TO BETTER OUTCOMES AFTER THE 0.19-mg FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT IN DIABETIC MACULAR EDEMA.
Gonzalez VH; Luo C; Almeida DRP; Cutino A; Coughlin B; Kasper J; Kiernan DF; ; ;
Retina; 2023 Aug; 43(8):1301-1307. PubMed ID: 37130434
[TBL] [Abstract][Full Text] [Related]
58. Changes in Ganglion Cell Layer Thickness after Treatment with the 0.2 µg/day Fluocinolone Acetonide Implant in Vitrectomized and Nonvitrectomized Eyes with Diabetic Macular Edema.
Pessoa B; Castro C; Ferreira A; Leite J; Heitor J; Menéres P; Figueira J; Meireles A; Beirão JM
Ophthalmic Res; 2022; 65(3):310-320. PubMed ID: 35086095
[TBL] [Abstract][Full Text] [Related]
59. Repeated intravitreous ranibizumab injections for diabetic macular edema and the risk of sustained elevation of intraocular pressure or the need for ocular hypotensive treatment.
Bressler SB; Almukhtar T; Bhorade A; Bressler NM; Glassman AR; Huang SS; Jampol LM; Kim JE; Melia M;
JAMA Ophthalmol; 2015 May; 133(5):589-97. PubMed ID: 25719991
[TBL] [Abstract][Full Text] [Related]
60. Combined fluocinolone acetonide intravitreal insertion and glaucoma drainage device placement for chronic uveitis and glaucoma.
Malone PE; Herndon LW; Muir KW; Jaffe GJ
Am J Ophthalmol; 2010 May; 149(5):800-6.e1. PubMed ID: 20189158
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]